Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Homo sapiens | sigma non-opioid intracellular receptor 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | amine GPCR | Dopamine D2 receptor | 444 aa | 424 aa | 32.1 % |
Loa Loa (eye worm) | hypothetical protein | Dopamine D2 receptor | 444 aa | 433 aa | 21.2 % |
Echinococcus multilocularis | serotonin receptor | Dopamine D2 receptor | 444 aa | 428 aa | 31.3 % |
Echinococcus multilocularis | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 465 aa | 21.5 % |
Onchocerca volvulus | RB1-inducible coiled-coil protein 1 homolog | Dopamine D2 receptor | 444 aa | 474 aa | 23.4 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Dopamine D2 receptor | 444 aa | 432 aa | 30.8 % |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Dopamine D2 receptor | 444 aa | 440 aa | 30.0 % |
Schistosoma japonicum | ko:K04207 neuropeptide Y receptor Y5, putative | Dopamine D2 receptor | 444 aa | 386 aa | 19.7 % |
Onchocerca volvulus | Dopamine D2 receptor | 444 aa | 418 aa | 23.0 % | |
Onchocerca volvulus | Glycoprotein hormone beta 5 homolog | Dopamine D2 receptor | 444 aa | 476 aa | 24.2 % |
Schistosoma mansoni | muscarinic acetylcholine (GAR) receptor | Dopamine D2 receptor | 444 aa | 487 aa | 23.8 % |
Echinococcus granulosus | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 457 aa | 21.0 % |
Schistosoma mansoni | biogenic amine (dopamine) receptor | Dopamine D2 receptor | 444 aa | 494 aa | 26.3 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Dopamine D2 receptor | 444 aa | 429 aa | 31.7 % |
Schistosoma mansoni | biogenic amine receptor | Dopamine D2 receptor | 444 aa | 452 aa | 30.1 % |
Schistosoma japonicum | Octopamine receptor, putative | Dopamine D2 receptor | 444 aa | 456 aa | 29.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | lanosterol synthase, putative | 0.0826 | 0.9369 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0445 | 0.3401 | 1 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0867 | 1 | 1 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0445 | 0.3401 | 0.5 |
Leishmania major | squalene monooxygenase-like protein | 0.0741 | 0.8043 | 0.7779 |
Trypanosoma cruzi | squalene monooxygenase, putative | 0.0741 | 0.8043 | 0.7035 |
Trypanosoma cruzi | squalene monooxygenase, putative | 0.0741 | 0.8043 | 0.7035 |
Mycobacterium tuberculosis | Halimadienyl diphosphate synthase | 0.0543 | 0.4943 | 0.5 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0867 | 1 | 1 |
Trypanosoma brucei | squalene monooxygenase, putative | 0.0741 | 0.8043 | 0.7035 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 88 nM | Binding affinity against sigma sites in guinea pig membrane using [3H]-DTG as the radioligand | ChEMBL. | 8426363 |
IC50 (binding) | = 88 nM | Binding affinity against sigma sites in guinea pig membrane using [3H]-DTG as the radioligand | ChEMBL. | 8426363 |
IC50 (binding) | = 205 nM | Binding affinity against sigma sites in guinea pig membrane using [3H]-(+)-3-PPP as the radioligand | ChEMBL. | 8426363 |
IC50 (binding) | = 205 nM | Binding affinity against sigma sites in guinea pig membrane using [3H]-(+)-3-PPP as the radioligand | ChEMBL. | 8426363 |
Ki (binding) | = 0.1 uM | Binding affinity against D2 receptor in rat corpus striatum using [3H]-sulpiride as the radioligand | ChEMBL. | 8426363 |
Ki (binding) | = 0.1 uM | Binding affinity against D2 receptor in rat corpus striatum using [3H]-sulpiride as the radioligand | ChEMBL. | 8426363 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.